Histone Demethylase

Demethylase

Histone Demethylase

Histone Demethylase Isoform Specific Products:

Histone Demethylase Related Products (221)
Antibodies (8)
Histone Demethylase Isoform Comparison

By Effects:	Controls (4) Ligand (1) Inhibitors (187) Degraders (3) Antagonist (1) Activators (6)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-B0660

Eicosapentaenoic Acid	Activator	98.70%
Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation.

HY-15648B

GSK-J4	Inhibitor	99.64%
GSK-J4 is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC₅₀s of 8.6 and 6.6 μM, respectively. GSK-J4 inhibits LPS-induced TNF-α production in human primary macrophages with an IC₅₀ of 9 μM. GSK J4 is a cell permeable proagent of GSK-J1. GSK-J4 induces endoplasmic reticulum stress-related apoptosis.

HY-12304

IOX1	Inhibitor	99.89%
IOX1, 5-Carboxy-8-hydroxyquinoline, is a potent broad‐spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases. IOX1 inhibits KDM4C, KDM4E, KDM2A, KDM3A and KDM6B with IC₅₀ values of 0.6 μM, 2.3 μM, 1.8 μM, 0.1 μM and 1.4 μM, respectively. IOX1 also inhibits ALKBH5.

HY-100421

CPI-455	Inhibitor	98.95%
CPI-455 is a specific, pan-KDM5 inhibitor with an IC₅₀ of 10 nM for KDM5A. CPI-455 mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents.

HY-18632

GSK2879552	Inhibitor	99.90%
GSK2879552 an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/ KDM1A), with potential antineoplastic activity.

HY-168433

LSD1/EGFR-IN-1	Inhibitor
LSD1/EGFR-IN-1 (compound L-1) is a potent inhibitor of LSD1, EGFR^T790M/L858R and EGFR^{L858R/T790M/C797S}, with IC₅₀s of 6.24 and 2.06 and 5.01 μM, respectively. LSD1/EGFR-IN-1 plays an important role in cancer research.

HY-168968S

ZJY-54
ZJY-54 is an orally active dual-target inhibitor of EGFR/LSD1, with IC₅₀ values of 3.8 nM and 0.6 μM, respectively. ZJY-54 can inhibit the proliferation of non-small cell lung cancer cells, induce the accumulation of H3K4me2 and H3K9me2, and inhibit the phosphorylation of the EGFR signaling pathway. ZJY-54 has anti-tumor activity.

HY-173136

KDM4 ligand-1	Ligand
KDM4 ligand-1 is a ligand for target protein (histone lysine demethylase KDM4) for PROTACs. KDM4 ligand-1 can be used in the synthesis of PROTACs (HY-173135).

HY-12782T

Iadademstat dihydrochloride	Inhibitor	99.98%
Iadademstat (ORY-1001) dihydrochloride is a selective irreversible lysine (K)-specific demethylase 1A (KDM1A/LSD1) inhibitor.

HY-13953

JIB-04	Inhibitor	98.29%
JIB-04 is a pan-selective Jumonji histone demethylase inihibitor with IC₅₀s of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.

HY-15648

GSK-J1	Inhibitor	99.94%
GSK-J1 is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A, with IC₅₀ of 60 nM towards KDM6B.

HY-103641

(2R)-Octyl-α-hydroxyglutarate	Control	99.91%
(2R)-Octyl-α-hydroxyglutarate ((2R)-Octyl-2-HG) is a modified form of D-isomer 2-Hydroxyglutarate.

HY-120400

KDM5-C70	Inhibitor
KDM5-C70 is an ethyl ester derivative of KDM5-C49 and a potent, cell-permeable and pan-KDM5 histone demethylase inhibitor. KDM5-C70 has an antiproliferative effect in myeloma cells, leading to genome-wide elevation of H3K4me3 levels.

HY-104048

QC6352	Inhibitor	99.13%
QC6352 is an orally active KDM4 inhibitor with anti-tumor and anti-proliferative activity. QC6352 has in vivo inhibitory effects on PDX models of breast and colon cancer and reduces the number of chemoresistant cell populations. QC6352 inhibits KDM4 different isoforms with IC₅₀s of 104 nM (KDM4A), 56 nM (KDM4B), 35 nM (KDM4C), and 104 nM (KDM4D), respectively. QC6352 has moderate inhibitory activity against KDM5 with an IC₅₀ of 750 nM (KDM5B).

HY-B1496

Tranylcypromine hemisulfate	Inhibitor	99.94%
Tranylcypromine (SKF 385) hemisulfate is an irreversible, nonselective monoamine oxidase (MAO) inhibitor used in the treatment of depression. Tranylcypromine hemisulfate is also a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis. Tranylcypromine has antidepressant effects.

HY-12635

SP2509	Antagonist	99.90%
SP2509 is a potent and selective antagonist of lysine specific demethylase 1 (LSD1) with an IC₅₀ of 13 nM.

HY-15648F

GSK-J4 hydrochloride	Inhibitor	99.01%
GSK-J4 hydrochloride is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC₅₀s of 8.6 and 6.6 μM, respectively. GSK-J4 hydrochloride inhibits LPS-induced TNF-α production in human primary macrophages with an IC₅₀ of 9 μM. GSK-J4 hydrochloride is a cell permeable proagent of GSK-J1.

HY-100546A

GSK-LSD1 dihydrochloride	Inhibitor	≥98.0%
GSK-LSD1 dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (LSD1) inhibitor with an IC₅₀ of 16 nM.

HY-103713

Seclidemstat	Inhibitor	99.77%
Seclidemstat is a potent noncompetitive and reversible KDM1A (LSD1) inhibitor (K_i=31 nM, IC₅₀=13 nM). Seclidemstat promotes antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, as well as inhibit virus production, viral DNA replication, and late gene expression. Seclidemstat can be used for the research of Ewing Sarcoma.

HY-116761

GSK467	Inhibitor	99.55%
GSK467 is a cell penetrant and selective KDM5B (JARID1B or PLU1) inhibitor with a K_i of 10 nM and an IC₅₀ of 26 nM. GSK467 shows 180-fold selectivity for KDM4C and no measurable inhibitory effects toward KDM6 or other Jumonji family members.

GSK-J4						KDM6		99.64%
IOX1		KDM2	KDM3	KDM4		KDM6		99.89%
CPI-455					KDM5			98.95%
GSK2879552	KDM1/LSD1							99.90%
Iadademstat dihydrochloride	KDM1/LSD1							99.98%
JIB-04				KDM4	KDM5	KDM6		98.29%
GSK-J1						KDM6		99.94%
KDM5-C70					KDM5
QC6352				KDM4A, IC₅₀: 104 nM KDM4B, IC₅₀: 56 nM KDM4C, IC₅₀: 35 nM KDM4D, IC₅₀: 104 nM	KDM5B, IC₅₀: 750 nM			99.13%
Tranylcypromine hemisulfate	KDM1/LSD1							99.94%
SP2509	KDM1/LSD1							99.90%
GSK-J4 hydrochloride						KDM6		99.01%
Seclidemstat	KDM1/LSD1							99.77%
GSK467					KDM5, Ki: 10 nM KDM5, IC₅₀: 26 nM			99.55%
Daminozide		KDM2						99.79%
AS8351					KDM5			99.88%
KDOAM-25 citrate					KDM5			98.11%
Pulrodemstat benzenesulfonate	KDM1/LSD1							99.64%
ML324				KDM4				98.46%
NCGC00244536				KDM4				99.70%
KDM5A-IN-1					KDM5			99.64%
Bomedemstat ditosylate	KDM1/LSD1							99.14%
PFI-90			KDM3					99.86%
Bomedemstat hydrochloride	KDM1/LSD1							99.94%
TK-129					KDM5, IC₅₀: 44 nM			≥98.0%
KDM2A/7A-IN-1		KDM2						99.94%
Bomedemstat dihydrochloride	KDM1/LSD1							99.55%
KDM5-IN-1					KDM5			99.52%
Iadademstat	LSD1							99.61%
TAK-418	KDM1/LSD1							99.81%
PBIT					KDM5			99.46%
KDM2/7-IN-1		KDM2		KDM4			KDM7	99.00%
KDM4D-IN-1				KDM4				98.82%
KDM4C-IN-1				KDM4				98.99%
S2101	KDM1/LSD1							99.73%
NSC636819				KDM4				98.90%
GSK 690 Hydrochloride	KDM1/LSD1							98.58%
YUKA1					KDM5			99.56%
DDP-38003 dihydrochloride	KDM1/LSD1							98.22%
T-3775440 hydrochloride	KDM1/LSD1							99.13%
KDM2B-IN-4		KDM2						99.59%
INCB059872 dihydrochloride	KDM1/LSD1							99.18%
JQKD82 trihydrochloride					KDM5			99.94%
LSD1/HDAC6-IN-2	LSD1, IC₅₀: 5 nM							99.66%
DDP-38003 trihydrochloride	KDM1/LSD1
INCB059872	KDM1/LSD1							98.06%
HDAC6-IN-3	KDM1/LSD1							≥98.0%
LSD1-IN-30	LSD1, IC₅₀: 0.291 μM							99.03%
CBB1007 trihydrochloride	KDM1/LSD1
Pulrodemstat	KDM1/LSD1
Bomedemstat	KDM1/LSD1							99.55%
KDM4-IN-2				KDM4				98.29%
Arborinine	LSD1							99.87%
NCGC00247743				KDM4				98.61%
CBB1007 hydrochloride	KDM1/LSD1							≥98.0%
GSK-J1 lithium salt						KDM6		98.33%
LSD1-IN-5	KDM1/LSD1
LSD1-IN-6	KDM1/LSD1
Pulrodemstat Methylbenzenesulfonate	KDM1/LSD1
CPI-455 hydrochloride					KDM5
LSD1/HDAC6-IN-1	KDM1/LSD1
LSD1-IN-13 hydrochloride	KDM1/LSD1
MC2652	KDM1/LSD1
KDM4-IN-4				KDM4A-Tudor domain, Ki: 80 μM
LSD1-IN-31	LSD1
LSD1-IN-34	LSD1, IC₅₀: 4.51 nM
HSP90/LSD1-IN-1	LSD1
LSD1-UM-109	LSD1, IC₅₀: 3.1 nM
LSD1-IN-38	LSD1, IC₅₀: 1.2 nM
S1427	KDM1/LSD1
LSD1-IN-23	KDM1/LSD1, IC₅₀: 0.58 μM
LSD1/2-IN-4	KDM1/LSD1
NCL1	LSD1, IC₅₀: 2.5 ± 0.5 μM
cis-4-Br-2,5-F2-PCPA	KDM1/LSD1
KDM1/CDK1-IN-1	KDM1/LSD1
LSD1/HDAC-IN-2	KDM1/LSD1, IC₅₀: 39.0 nM
LSD1-IN-26	LSD1, IC₅₀: 25.3 ± 1.4 nM
LSD1-IN-21	LSD1, IC₅₀: 0.956 μM
KDM5-C49					KDM5
LSD1-IN-35	LSD1
LSD1-IN-18	KDM1/LSD1
LSD1-IN-25	LSD1, IC₅₀: 46 nM LSD1, Ki: 30.3 nM
(1S,2R)-Tranylcypromine hydrochloride	KDM1/LSD1
LSD1-IN-22	KDM1/LSD1
LSD1-IN-39	LSD1, IC₅₀: 0.18 μM
LSD1-IN-19	KDM1/LSD1
LSD1-IN-42	LSD1, IC₅₀: 0.08 μM
LSD1/2-IN-3	KDM1/LSD1
Tranylcypromine-d₅ hydrochloride	KDM1/LSD1
LSD1/HDAC-IN-1	LSD1, IC₅₀: 0.571 μM
JQKD82					KDM5
LSD1/ER-IN-1	KDM1/LSD1
LSD1-IN-36	LSD1, IC₅₀: 0.8 nM
CBB1003 hydrochloride	KDM1/LSD1

Name
Email *

	Sorry, but the email address you supplied was invalid.

Histone Demethylase

Histone Demethylase

Histone Demethylase Isoform Specific Products:

Histone Demethylase Isoform Specific Products:

Histone Demethylase Related Products (221)

Antibodies (8)

Histone Demethylase Isoform Comparison

Histone Demethylase Related Products (221):